Lutropin Alpha

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Luveris; Belgium: Luveris; Cyprus: Luveris; Czech Republic: Luveris; Denmark: Luveris; Estonia: Luveris; Finland: Luveris; France: Luveris; Germany: Luveris; Greece: Luveris; Hungary: Luveris; Ireland: Luveris; Italy: Luveris; Latvia: Luveris; Lithuania: Luveris; Luxembourg: Luveris; Malta: Luveris; Netherlands: Luveris; Poland: Luveris; Portugal: Luveris; Romania: Luveris; Slovakia: Luveris; Slovenia: Luveris; Spain: Luveris; Sweden: Luveris; UK: Luveris.

North America

Canada: Luveris; USA: Luveris.

Latin America

Argentina: Luveris; Mexico: Luver-I.S.

Drug combinations

Lutropin Alpha and Follitropin Alpha


Lutropin Alpha: C~437~H~682~N~122~O~134~S~13.~ Mw:10205.69 (α – subunit); C~577~H~929~N~165~O~161~S~14~ Mw: 13,202.49 (β-subunit). (1) Luteinizing hormone (human α-subunit reduced), complex with luteinizing hormone (human β-subunit reduced), glycoform α. CAS-152923-57-4; CAS-56832-30-5 (α-subunit); CAS-53664-53-2 (β-subunit)(2001).

Pharmacologic Category

Hormones and Synthetic Substitutes; Gonadotropins. Gonadotropin. Ovulation Stimulator. (ATC-Code: G03GA07).

Mechanism of action

Recombinant luteinizing hormone prepared using Chinese hamster cell ovaries. Increases follicular estradiol secretion.

Therapeutic use

Stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound luteinizing hormone deficiency. To be used in combination with follitropin alpha.

Pregnancy and lactiation implications

Contraindicated for use during pregnancy (increase in pre-/postimplantation loss observed in animal studies).

Unlabeled use


Hypersensitivity to lutropin alpha or any component of the formulation. Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Uncontrolled organic intracranial lesion. Abnormal uterine bleeding of undetermined origin. Ovarian cyst or enlargement of undetermined origin. Sex hormone-dependent tumors of reproductive tract and accessory organs. Pregnancy.

Warnings and precautions

Ovarian enlargement might be accompanied by abdominal distention or abdominal pain. Ovarian hyperstimulation syndrome (severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria; may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events) might occur. Thromboembolic events reported. Use with caution in hepatic and renal impairment. Multiple births might result from use of these medications.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart